Uplizna (inebilizumab) reduced the frequency of disease exacerbations, or periods when symptoms worsen, and the need for rescue therapy in people with generalized myasthenia gravis (gMG). That’s according to a prespecified analysis of data from the global Phase 3 MINT clinical trial (NCT04524273), which showed that after…
News
Myasthenia gravis (MG) is the strongest predictor of complications after a thymectomy, a surgery to remove a tumor of the thymus gland, according to a study in China. The risk of post-surgery complications was more than seven times higher in people with MG. Other factors independently associated with complication…
Vyvgart (efgartigimod alfa-fcab), an approved treatment for myasthenia gravis (MG), can quickly and safely ease symptoms in people with the rare neuromuscular disease who are experiencing severe flare-ups, a new study suggests. Although the study was limited to a small number of patients, the researchers said the data…
Top-line results — a snapshot of key early findings — from a large international clinical trial testing Immunovant’s therapy candidate IMVT-1402 in adults with generalized myasthenia gravis (gMG) are expected next year, according to the developer. The trial, involving an estimated 231 participants at 88 locations worldwide, is…
In a global late-stage trial testing gefurulimab for generalized myasthenia gravis (gMG), the injection treatment candidate was shown to safely and effectively ease gMG symptoms — per both patient-reported and physician-rated scales. That’s according to the final results from this Phase 3 clinical trial, called PREVAIL (NCT05556096),…
Different forms of myasthenia gravis (MG) may have distinct patterns of immune system activity, with MG that appears before age 50 and MG driven by antibodies against the muscle-specific kinase (MuSK) protein showing stronger activity, a study found. “These findings underscore the immunological [variability] of MG and suggest that…
Long-term rituximab treatment safely and effectively eased symptoms and reduced the need for anti-inflammatory corticosteroids in adults with hard-to-treat generalized myasthenia gravis (gMG), according to a small, real-world study in Italy. The benefits were seen in patients with the two most common gMG-driving self-reactive antibodies, but were greater…
Adding Imaavy (nipocalimab-aahu) to standard treatment reduces hospital days by as much as 68% and lowers estimated annual hospital costs by $11,000 to $13,000 per patient for adults with generalized myasthenia gravis (gMG). That’s according to a post hoc analysis of data from the global Phase 3…
Argenx is advancing a clinical trial evaluating whether adding the experimental therapy empasiprubart to Vyvgart (efgartigimod alfa-fcab) can improve disease control in people with generalized myasthenia gravis (gMG) whose symptoms are only partly controlled with Vyvgart alone. The Phase 2a clinical trial, called ADAPT-Forward 1 (NCT07284420), is…
Kyverna Therapeutics and ElevateBio have signed a manufacturing and supply agreement for mivocabtagene autoleucel (miv-cel), Kyverna’s experimental CAR T-cell therapy for people with generalized myasthenia gravis (gMG). The new agreement covers both U.S. commercial and global clinical supply of miv-cel, formerly known as KYV-101, which is currently…
Recent Posts
- How an MG diagnosis changed our lives forever
- Bionews survey finds positive and negative emotions coexist in MG
- MDA Engage: National ambassador brings message of belonging, resilience
- gMG treatments show varied benefits across response measures
- Like a donkey, my MG body is stubborn, but it has also carried me